MECHANISM-BASED INACTIVATION OF CYP2C11 BY DICLOFENAC

Transcription

1 /01/ $3.00 DRUG METABOLISM AND DISPOSITION Vol. 29, No. 9 Copyright 2001 by The American Society for Pharmacology and Experimental Therapeutics 400/ DMD 29: , 2001 Printed in U.S.A. MECHANISM-BASED INACTIVATION OF CYP2C11 BY DICLOFENAC YASUHIRO MASUBUCHI, ATSUSHI OSE, AND TOSHIHARU HORIE Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan (Received March 19, 2001; accepted May 16, 2001) This paper is available online at ABSTRACT: It has been known that diclofenac is biotransformed into chemically reactive metabolites, which bind covalently to liver microsomal proteins, including cytochrome P450 enzyme(s). We have investigated the ability and selectivity of diclofenac to inactivate P450 enzymes. Preincubation of microsomes of untreated rats with diclofenac in the presence of NADPH resulted in time-dependent loss of testosterone 2 - and 16 -hydroxylation activities. No effect of the preincubation was observed on ethoxyresorufin O-deethylase, pentoxyresorufin O-depentylase, or testosterone 6 -hydroxylation activity. The time-dependent decreases in testosterone 2 - and 16 -hydroxylation activities followed the pseudo-first order kinetics and were saturable with increasing diclofenac concentrations. Reduced glutathione was not capable of protecting against the decrease in the enzyme activities. These data establish that a mechanism-based inactivation of CYP2C11 occurs during the oxidative metabolism of diclofenac. The diclofenac concentrations required to achieve the half-maximal rate of inactivation (K I ) Diclofenac is one of the nonsteroidal anti-inflammatory drugs widely used clinically. In relation to the diclofenac-induced hepatotoxicity, extensive studies have focused on biotransformation of diclofenac into chemically reactive metabolites capable of binding covalently to liver macromolecules (Boelsterli et al., 1995). Some protein targets of the reactive metabolites have been identified in the liver of animals administrated the drug (Pumford et al., 1993; Hargus et al., 1995; Wade et al., 1997; Seitz et al., 1998). In vitro studies with hepatocytes also showed the formation of the reactive metabolites (Kretz-Rommel and Boelsterli, 1994b; Gil et al., 1995). UDP-glucuronosyltransferase and cytochrome P450 (CYP 1 ) enzymes were shown to mediate the metabolic activation (Kretz-Rommel and Boelsterli, 1993, 1994a; Hargus et al., 1994). Acyl glucuronide is a common metabolite of carboxylic acid drugs such as acidic nonsteroidal anti-inflammatory drugs, which is often demonstrated as a reactive metabolite of these drugs (Spahn-Langguth This study was supported in part by a grant-in-aid from the Ministry of Education, Science, and Culture of Japan. 1 Abbreviations used are: CYP, cytochrome P450; GSH, reduced glutathione; G-6-P, glucose 6-phosphate; G-6-PDH, glucose 6-phosphate dehydrogenase; HPLC, high-performance liquid chromatography; EROD, ethoxyresorufin O-deethylase; PROD, pentoxyresorufin O-depentylase. Address correspondence to: Dr. Toshiharu Horie, Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Chiba University, 1-33 Yayoi-cho, Inage-ku, Chiba , Japan. horieto@p.chiba-u.ac.jp 1190 were3to4 M, which were close to K m for the low-k m components for diclofenac 4 - and 5-hydroxylation activities (7.29 and 4.43 M, respectively). Anti-CYP2C11 IgG inhibited diclofenac 4 and 5-hydroxylation activities, indicating that CYP2C11 is a major isozyme responsible for these aromatic oxidations. The preincubation of microsomes with 4 - or 5-hydroxydiclofenac did not cause a decrease in testosterone 2 -or16 -hydroxylation activity, suggesting that neither of the primary metabolites is a precursor of the metabolite that inactivates CYP2C11. Therefore, a highly reactive intermediate(s) inactivating CYP2C11, probably arene-oxide, appears to be generated during the process of diclofenac 4 and/or 5-hydroxylation. Diclofenac metabolism in human liver microsomes did not cause inactivation of CYP2C9, a major isozyme involved in diclofenac 4 -hydroxylation. Because the human microsomes have high diclofenac 4 -hydroxylation but not 5-hydroxylation activity, importance of the latter pathway in the inactivation is suggested. and Benet, 1992; Boelsterli et al., 1995). The reactivity and potential toxicity of acyl glucuronide products are widely recognized (Kretz- Rommel and Boelsterli, 1993, 1994a; Hargus et al., 1994). It is known that diclofenac is oxidized mainly into two phenolic metabolites, 4 -hydroxydiclofenac and 5-hydroxydiclofenac (Stierlin et al., 1979) (Fig. 1). Although quinone imine metabolite of 5-hydroxydiclofenac has been proposed as a reactive metabolite of diclofenac (Brune and Lindner, 1992), definitive proof for the chemical structure of reactive metabolite by CYP enzymes had not been available. Recent studies provided information about the chemical nature of the reactive metabolite and CYP enzymes involved in its formation. Tang et al. (1999a) found benzoquinone imines as their reduced glutathione (GSH) conjugates, which were formed from 4 - and 5-hydroxydiclofenac in rats and human hepatocytes. They also isolated the GSH conjugates of benzoquinone metabolites in incubations of human liver microsomes with diclofenac in the presence of NADPH and GSH (Tang et al., 1999b). Shen et al. (1999) reported that covalent binding of diclofenac to human liver microsomes was CYP3A4-dependent, and benzoquinone imine, a decomposition product of 5-hydroxydiclofenac, bound covalently to human liver microsomes. Bort et al. (1999) reported that N,5-dihydroxydiclofenac was also found as a further metabolite of 5-hydroxydiclofenac, which was proposed to contribute to the hepatotoxicity of diclofenac. If a product formed by CYP-dependent metabolism is highly reactive, it should bind to the site of formation in the enzyme, resulting in mechanism-based inactivation of the CYP enzyme. The diclofenac metabolism to generate the benzoquinone metabolites mentioned

2 DICLOFENAC INACTIVATES CYP2C FIG. 1.Major pathways for oxidative metabolism of diclofenac in rat liver microsomes. above was shown to be catalyzed by CYP2B, CYP2C, and CYP3A enzymes in rats (Tang et al., 1999a), whereas it has been proposed that CYP2C11 is a target of a reactive metabolite of diclofenac in rat liver microsomes (Shen et al., 1997). In the present study, to investigate the relationship between the abilities of CYP enzymes to activate diclofenac and their tendency to be targets of the metabolites formed from diclofenac, we tested the ability and selectivity of diclofenac to inactivate CYP enzymes, including CYP2B, CYP2C, and CYP3A, in rat liver microsomes. The chemical nature of the reactive metabolite involved in the inactivation is also discussed. Materials and Methods Chemicals. Diclofenac sodium, GSH, and tolbutamide were purchased from Wako Pure Chemical (Osaka, Japan); testosterone, 2 -hydroxytestosterone, and 16 -hydroxytestosterone, ethoxyresorufin, and pentoxyresorufin were from Sigma (St. Louis, MO); 6 -hydroxytestosterone was from Steraloids Inc. (Wilton, NH); resorufin and sodium phenobarbital were from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan); -naphthoflavone was from Aldrich (Milwaukee, WI); and hydroxytolbutamide was from Ultrafine Chemicals (Manchester, UK). 4 -Hydroxydiclofenac and 5-hydroxydiclofenac were gifts from Novartis Pharma AG (Basel, Switzerland). Glucose 6-phosphate (G-6-P), glucose 6-phosphate dehydrogenase (G-6-PDH), and NADPH were purchased from Oriental Yeast Co., Ltd. (Tokyo, Japan). All other chemicals and solvents used were of analytical grade. Liver Microsomes and P450 Enzyme. Male Wistar rats (2-months old) were obtained from Takasugi Experimental Animals (Saitama, Japan). The animals were housed in an air-conditioned room (25 C) under a 12-h light/dark cycle for 1 week before use. Food (commercially available pellet; Oriental Yeast Co., Ltd.) and water were given ad libitum. Sodium phenobarbital (80 mg/kg in physiological saline) or -naphthoflavone (80 mg/kg in corn oil) was given to the rats intraperitoneally for 4 days. The rats were killed along with untreated rats by decapitation 24 h after the final doses, and liver microsomal fractions were prepared according to the method of Omura and Sato (1964). Protein concentrations were assayed by the method of Lowry et al. (1951). Recombinant CYP2C11 expressed in microsomes of insect cells infected with baculovirus containing rat NADPH-P450 reductase and human cytochrome b 5, and human liver microsomes (pooled fraction from 12 patients) were purchased from GENTEST (Woburn, MA). Preincubation of Liver Microsomes with Diclofenac and Its Metabolites. Liver microsomes of untreated or inducer-treated male Wistar rats, microsomes from insect cells expressing CYP2C11, and pooled human liver microsomes were preincubated with diclofenac in the presence of NADPH to determine effects of the metabolic intermediates on microsomal monooxygenase activities. A 1-ml incubation mixture contained microsomes (0.5 mg of rat liver microsomes, 10 pmol of CYP2C11, or 0.25 mg of human liver microsomes), 10 mm G-6-P, 2 units of G-6-PDH, 10 mm MgCl 2, 0.1 mm EDTA, and various concentrations of diclofenac in 0.15 M potassium phosphate buffer, ph 7.4). In some experiments, primary metabolites of diclofenac were used instead of diclofenac. After temperature equilibration (37 C, 5 min), preincubation of microsomes with diclofenac was started by adding NADPH (final 0.5 mm) and performed for various time periods up to 15 min (30 min for human). The subsequent incubation of the microsomes for the assay of enzymatic activities was started by the addition of a test substrate, testosterone, ethoxyresorufin, pentoxyresorufin, or tolbutamide. Testosterone 2 -, 16 -, and 6 -hydroxylation activities of the preincubated microsomes were determined according to the high-performance liquid chromatography (HPLC) method previously described (Masubuchi et al., 1995) at the testosterone concentration of 50 M. Ethoxyresorufin O-deethylase (EROD) and pentoxyresorufin O-depentylase (PROD) activities of the microsomes were assayed by the fluorometric method to determine the resorufin formation (Burke et al., 1985) at the substrate concentrations of 1 and 5 M, respectively. Tolbutamide methyl-hydroxylation activity was determined according to the HPLC method previously described (Miners et al., 1988) at the tolbutamide concentration of 2 mm. Liver microsomes from untreated rats were used for assays of testosterone oxidation activities; those from phenobarbital-treated rats were for PROD activity assays; those from -naphthoflavone-treated rats were for EROD activity assays; and human liver microsomes were for tolbutamide hydroxylation activity. All of the assays were performed under linear conditions of metabolite formation with regard to incubation time and protein concentration. Assay of Diclofenac 4 - and 5-Hydroxylation Activities. Diclofenac 4 and 5-hydroxylation activities were assayed according to the HPLC method of Leemann et al. (1993) with modifications. A 1-ml incubation mixture contained 0.5 mg of liver microsomes, 10 mm G-6-P, 2 units of G-6-PDH, 5 mm MgCl 2, and various concentrations of diclofenac (1 320 M) in 0.15 M potassium phosphate buffer, ph 7.4). After temperature equilibration (37 C, 5 min), the reaction was started by adding NADPH (final 0.5 mm), and the incubation was performed for 2.5 min. The reaction was terminated by 1 M sodium phosphate buffer, ph 5.0 and then flurbiprofen was added to the mixture as an internal standard. Diclofenac and its metabolites were extracted into diethyl ether, the organic layer was evaporated to dryness, and the residue was dissolved in 0.1 ml of a mobile phase for the HPLC, which consists of 100 mm sodium phosphate buffer, ph 7.4, including 0.02% triethanolamine and acetonitrile (7:3 by vol). The sample was applied to a reversed phase column (Inertsil ODS; GL Sciences Ltd., Tokyo, Japan). The UV absorbance intensity of diclofenac metabolites was monitored at 282 nm. Immunoinhibition of Diclofenac Metabolism by an Antibody against CYP2C11. A polyclonal antibody against CYP2C11 raised in a goat was obtained from Daiichi Pure Chemicals (Tokyo, Japan). In immunoinhibition studies, microsomes were preincubated with various amounts of the antibody or preimmune serum at 25 C for 30 min, followed by adding other components of the incubation mixture and assay of diclofenac 4 - and 5-hydroxylation activities. Data Analysis. Enzyme kinetic parameters (K m, V max ) were analyzed according to a nonlinear least-squares regression analysis based on a simplex method (Yamaoka et al., 1981). Best fittings of the data were performed by weighting them with the reciprocal of the square of the activity. Pseudo-first order kinetic constants for the enzyme inactivation (k) were calculated from the initial slopes of the linear regression lines of the semilogarithmic plots of the remaining enzyme activity against the preincubation time. The reciprocal of k thus obtained was plotted against the reciprocal of the diclofenac concentration and then a concentration required for a half-maximum inactivation (K I ) for the inactivation and a maximum inactivation rate constant (k inact ) were determined from the intercepts on the abscissa and the ordinate, respectively. Results were represented as means S.E. Statistical significance was calculated by the Student s t test. For experiment involving more than two experimental groups, the groups were compared by analysis of variance, followed by Newman-

3 1192 MASUBUCHI ET AL. FIG. 2.Time- and concentration-dependent decrease in testosterone oxidation activities during preincubation of microsomes with diclofenac. Microsomes from untreated male rats were preincubated without (E) or with diclofenac (2.5 M, Œ; 5 M, F; 10 M, ) in the presence of NADPH, followed by assay of testosterone 2 - and 16 -hydroxylation activities. Results are means S.E. (n 3). Keuls multiple comparison test to determine significant differences between the group means. FIG. 3.Double reciprocal plots of the first order rate constant for inactivation of testosterone hydroxylases versus diclofenac concentration. Microsomes from untreated male rats were preincubated without or with diclofenac (2.5, 5, 10 M) in the presence of NADPH, followed by assay of testosterone 2 - and 16 -hydroxylation activities. Pseudo-first order kinetic constants for the enzyme inactivation (k) were calculated from the initial slopes of the linear regression lines of the semilogarithmic plots of the remaining enzyme activity against the preincubation time as shown in Fig. 2. The reciprocal of k thus obtained was plotted against the reciprocal of the diclofenac concentration. Results are means S.E. (n 3). TABLE 1 Kinetic parameters for testosterone hydroxylation in rat liver microsomes undergoing inactivation in the presence of diclofenac K I for the inactivation and a maximum inactivation rate constant (k inact ) were determined from the intercepts on the abscissa and the ordinate in Fig. 3, respectively. Results are means S.E. (n 3). Results Effect of Diclofenac Metabolism on Testosterone 2 - and 16 - Hydroxylation Activities. Diclofenac inhibited testosterone 2 - and 16 -hydroxylation activities, which were used as indicators of CYP2C11 activity, with an IC 50 value of approximately 60 M atthe testosterone concentration of 50 M (data not shown). Preincubation of liver microsomes from untreated male rats in the presence of NADPH with diclofenac intensified the inhibitory effect of diclofenac (Fig. 2). The time-dependent decreases in the activities indicate inactivation of CYP2C11 during metabolism of diclofenac. The decreases in testosterone 2 - and 16 -hydroxylation activities were exponential against the preincubation time and depended on the diclofenac concentration. The first order kinetic constants for the enzyme inactivation (k) were calculated from the initial slopes of the linear regression lines of the semilogarithmic plots of the remaining enzyme activity (Fig. 2). The reciprocal of k thus obtained was plotted against the reciprocal of the diclofenac concentration (Fig. 3). The diclofenac concentrations required to achieve the half-maximal rate of inactivation (K I )were3to4 M (Table 1). Effect of GSH on Diclofenac-Induced Decreases in Testosterone 2 - and 16 -Hydroxylation Activities. Liver microsomes were preincubated with diclofenac and NADPH in the presence or absence of GSH to determine its protective effect against the inhibition of testosterone 2 - and 16 -hydroxylation activity by the diclofenac metabolism. The decrease in the activity by the preincubation of microsomes was observed both without and with GSH at the concentration of 5 mm (Fig. 4). Effect of Diclofenac Metabolism on Other Monooxygenase Activities. The preincubation of microsomes with diclofenac did not affect EROD activity in liver microsomes of -naphthoflavonetreated rats (an indicator of CYP1A), PROD activity in microsomes of phenobarbital-treated rats (CYP2B), or testosterone 6 -hydroxylation activity in microsomes of untreated rats (CYP3A) (Fig. 5). These results indicated selectivity for CYP2C11 in the inactivation during the diclofenac metabolism. Kinetics for Diclofenac 4 - and 5-Hydroxylation Activities. Kinetic analysis for diclofenac 4 - and 5-hydroxylation activities obtained in the substrate concentration range of 1 to 320 M indicated that both of the reactions were catalyzed by more than two enzyme systems. K m values for the low-k m components for diclofenac 4 hydroxylation and 5-hydroxylation activities (7.29 and 4.43 M, respectively; Table 2) were close to the K I for the inactivation (3 4 M; Table 1). Partition ratio of sum of diclofenac 4 - and 5-hydroxylation (diclofenac elimination is almost equivalent to the sum) versus the rate of inactivation was calculated to be Effects of Primary Metabolites of Diclofenac on Testosterone 2 - and 16 -Hydroxylation Activities. Addition of primary metabolites of diclofenac, 4 -hydroxydiclofenac, and 5-hydroxydiclofenac, at the concentration that diclofenac inhibited testosterone 2 - and 16 -hydroxylation activities, did not affect either of the activities (Fig. 6). Preincubation of microsomes with the metabolite in the presence of NADPH did not cause a decrease in testosterone 2 - or 16 -hydroxylation activity (Fig. 6). Similar results were obtained by the preincubation of microsomes with the metabolite but in the absence of NADPH (data not shown). Diclofenac Metabolism and Inactivation of CYP2C11 Expressed in Microsomes of Insect Cells with Baculovirus System. Effects of diclofenac metabolism on CYP2C11 were also tested using microsomes from insect cells expressing CYP2C11 instead of rat liver K I k inact M min 1 2 -Hydroxylation Hydroxylation

4 DICLOFENAC INACTIVATES CYP2C FIG. 4.Effect of GSH on decreases in testosterone oxidation activities during diclofenac metabolism. Microsomal reaction mixture was preincubated with NADPH in the absence or presence of diclofenac (10 M) and GSH (5 mm) for 10 min, followed by assay of testosterone 2 - and 16 -hydroxylation activities. Results are means S.E. (n 3). The groups were compared by analysis of variance, followed by Newman-Keuls multiple comparison test., significantly different from the control activity obtained without diclofenac (p 0.01). FIG. 5.Lack of effect of preincubation of microsomes with diclofenac on archetypal monooxygenase activities. Microsomes from -naphthoflavone-treated, phenobarbital-treated, and untreated male rats were preincubated without (E) or with (F) diclofenac (10 M) in the presence of NADPH, followed by assay of EROD, PROD, and testosterone 6 -hydroxylation activities, respectively. Results are means S.E. (n 3). FIG. 6.Effects of primary metabolites of diclofenac and the preincubation of microsomes with them on testosterone oxidation activities. Microsomes were not preincubated ( ) or preincubated for 10 min (o) with diclofenac (D), 4 -hydroxydiclofenac (4 -OH-D), or 5-hydroxydiclofenac (5-OH-D) at the concentration of 10 M in the presence of NADPH, followed by assay of testosterone 2 - and 16 -hydroxylation activities. Results are represented as percentage of the control activity obtained without diclofenac or the metabolite, and are means S.E. (n 3). The control testosterone 2 -hydroxylation activities are (not preincubated) and (preincubated) nmol/min/mg of protein, and the control testosterone 16 -hydroxylation activities are (not preincubated) and (preincubated) nmol/min/mg of protein.,, significantly different from control (p 0.05, p 0.01, respectively) calculated by the Student s t test. TABLE 2 Kinetic parameters for diclofenac 4 - and 5-hydroxylation in liver microsomes of male rats Parameters were calculated from the metabolic activities obtained at the substrate concentration range of 1 to 320 M. Results are means S.E. (n 3). K m1 V max1 K m2 V max2 M nmol/min/mg M nmol/min/mg 4 -Hydroxylation Hydroxylation microsomes. Testosterone 16 -hydroxylation activity rapidly decreased during the preincubation of expressed CYP2C11 with diclofenac in the presence of NADPH (Fig. 7). The first order kinetic constants for the enzyme inactivation thus obtained from the initial slope were min 1. It was observed that CYP2C11 had an ability to generate 4 - and 5-hydroxydiclofenac (1.8 pmol/min/pmol of CYP FIG. 7.Time-dependent decrease in testosterone 16 -hydroxylation activity of recombinant CYP2C11 during diclofenac metabolism. Microsomes from insect cells expressing CYP2C11 with a baculovirus expression system were preincubated without (E) or with diclofenac (10 M) (F) inthe presence of NADPH, followed by assay of testosterone 16 -hydroxylation activity. Results are means duplicate experiments. for 4 -hydroxylation, 2.2 pmol/min/pmol of CYP for 5-hydroxylation, at the diclofenac concentration of 10 M). Effect of Antibody against CYP2C11 on Diclofenac 4 - and 5-Hydroxylation Activities. Effect of addition of a polyclonal anti-

5 1194 MASUBUCHI ET AL. FIG. 8.Inhibition of diclofenac 4 - and 5-hydroxylation activities by a polyclonal antibody against CYP2C11. Microsomes from untreated male rats were preincubated with anti-cyp2c11 antiserum (F) or preimmune serum (E), followed by assay of diclofenac 4 - and 5-hydroxylation activities at diclofenac concentrations of 10 M. Relative activities are represented as percentage of the activity obtained without the antibody, and are means of duplicate determinations. body against CYP2C11 on diclofenac 4 - and 5-hydroxylation activities in liver microsomes of untreated male rats was tested at a diclofenac concentration of 10 M. The antibody inhibited both diclofenac 4 - and 5-hydroxylation activities in the concentrationdependent manner, causing complete inhibition at the serum/microsomal protein concentration ratio of 40 (Fig. 8). Effect of Diclofenac Metabolism on Tolbutamide Hydroxylation Activity in Human Liver Microsomes. Kinetic analysis for diclofenac metabolism with pooled human liver microsomes indicated K m and V max for diclofenac 4 -hydroxylation activity was 3.65 M and 1.83 nmol/min/mg of protein, whereas we could not obtain the exact parameter for 5-hydroxylation because of the low activity (approximately 0.01 nmol/min/mg of protein at the diclofenac concentration of 100 M). CYP2C9 is a major CYP isozyme responsible for diclofenac 4 -hydroxylation in human. We examined the effect of the preincubation of the microsomes with diclofenac (100 M) in the presence of NADPH on tolbutamide hydroxylation as an indicator of CYP2C9. Although tolbutamide hydroxylation activity was decreased by the addition of diclofenac because of competitive inhibition, the preincubation did not intensify the inhibitory effect (Fig. 9). Discussion A previous immunochemical study has demonstrated that CYP2C11 is one of the microsomal target proteins of covalent binding of the diclofenac reactive metabolite (Shen et al., 1997). It was demonstrated that diclofenac inactivated CYP2C11 in a mechanismbased manner according to the following observations (Figs. 2 4): 1) NADPH dependence for the inhibition, 2) pseudo-first order kinetics for the time-dependent inactivation, 3) saturability of inactivation with increasing diclofenac concentrations, and 4) lack of protection against the inhibition by GSH. Selectivity toward one particular CYP enzyme, CYP2C11 in this case, is characteristic of suicide inactivation. More rapid inactivation of CYP2C11, which was observed by using expressed CYP2C11 instead of liver microsomes (Fig. 7), supported the conclusion. FIG. 9.Lack of effect of diclofenac metabolism on tolbutamide hydroxylation activity in human liver microsomes. Human liver microsomes were preincubated without (E) or with (F) diclofenac (100 M) in the presence of NADPH, followed by assay tolbutamide hydroxylation activity. Results are means S.E. (n 3). The diclofenac concentrations required to achieve the half-maximal rate of inactivation (K I )were3to4 M. Kinetic analysis for diclofenac 4 - and 5-hydroxylation activities indicated that both of the reactions were catalyzed by more than one enzyme system (Table 2). The K I value for the inactivation were close to K m values for the low-k m components for diclofenac 4 - and 5-hydroxylation activities (7.29 and 4.43 M, respectively), suggesting that the pathway(s) is relevant to the inactivation of CYP2C11. There can be two ways to generate the reactive metabolite(s). One possibility is that the process of diclofenac 4 - and/or 5-hydroxylation is directly involved in generation of a reactive intermediate(s). Areneoxide is one of the proposed metabolic intermediates generated during the aromatic hydroxylations, which are highly reactive and are involved in enzyme inactivation. A second possibility is that further metabolites of 4 - and 5-hydroxydiclofenac, which include benzoquinones and hydroxylamine and have been already proposed in relation to the diclofenac hepatotoxicity (Brune and Lindner, 1992; Bort et al., 1999; Shen et al., 1999; Tang et al., 1999a,b). However, the preincubation of microsomes with 4 - or 5-hydroxydiclofenac instead of diclofenac did not cause decrease in testosterone 2 -or16 -hydroxylation activity (Fig. 6), indicating that the proposed further metabolite is not responsible for the inactivation of CYP2C11. We found that both aromatic hydroxylations of diclofenac were mediated by CYP2C11 (Fig. 7). Thus, it is concluded that diclofenac inactivates CYP2C11 during the 4 - and/or 5-hydroxylation processes, probably via the arene-oxide formation. Human liver microsomes have higher diclofenac 4 -hydroxylation activity compared with rats, whereas 5-hydroxylation activity was very low. There was no evidence for mechanism-based inactivation of CYP2C9, a major CYP isozyme responsible for diclofenac 4 -hydroxylation, during the diclofenac metabolism in human liver microsomes (Fig. 9). It is reasonable to postulate that the reactive metabolite relevant to inactivation of CYP enzymes is not generated during diclofenac 4 -hydroxylation. Thus, diclofenac 5-hydroxylation rather

6 DICLOFENAC INACTIVATES CYP2C than 4 -hydroxylation seems to be closely related to formation of arene-oxide, a possible candidate to inactivate CYP2C11. However, the possibility could not be excluded that diclofenac 4 -hydroxylation was mediated by CYP2C11 and CYP2C9 via different intermediates. In summary, diclofenac is demonstrated to be a selective and mechanism-based inactivator of CYP2C11. Formation of a chemically reactive metabolite of diclofenac that inactivates CYP2C11 was a low-k m reaction. The major pathways leading to aromatic hydroxylations, especially 5-hydroxylation, appear to be directly involved in the formation of the intermediate that binds to CYP2C11, resulting in loss of catalytic activity. References Boelsterli UA, Zimmerman HJ and Kretz-Rommel A (1995) Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology. Crit Rev Toxicol 25: Bort R, Ponsoda X, Jover R, Gomez-Lechon MJ and Castell JV (1999) Diclofenac toxicity to hepatocytes: a role for drug metabolism in cell toxicity. J Pharmacol Exp Ther 288: Brune K and Lindner J (1992) Increased liver toxicity of diclofenac by paracetamol: results and possible mechanisms, in Inflammation and Drug Therapy Series. Side-Effects of Anti- Inflammatory Drugs 3 (Rainsford KD and Velo GP eds) vol 5, pp , Kluwer Academic Publishers, Dordrecht, Lancaster. Burke MD, Thompson S, Elcombe CR, Halpert J, Haaparanta T and Mayer RT (1985) Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450. Biochem Pharmacol 34: Gil ML, Ramirez MC, Terencio MC and Castell JV (1995) Immunochemical detection of protein adducts in cultured human hepatocytes exposed to diclofenac. Biochim Biophys Acta 1272: Hargus SJ, Amouzedeh HR, Pumford NR, Myers TG, McCoy SC and Pohl LR (1994) Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 7: Hargus SJ, Martin BM, George JW and Pohl LR (1995) Covalent modification of rat liver dipeptidyl peptidase IV (CD26) by the nonsteroidal anti-inflammatory drug diclofenac. Chem Res Toxicol 8: Kretz-Rommel A and Boelsterli UA (1993) Diclofenac covalent protein binding is dependent on acyl glucuronide formation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes. Toxicol Appl Pharmacol 120: Kretz-Rommel A and Boelsterli UA (1994a) Mechanism of covalent adduct formation of diclofenac to rat hepatic microsomal proteins. Retention of the glucuronic acid moiety in the adduct. Drug Metab Dispos 22: Kretz-Rommel A and Boelsterli UA (1994b) Selective protein adducts to membrane proteins in cultured rat hepatocytes exposed to diclofenac: radiochemical and immunochemical analysis. Mol Pharmacol 45: Leemann T, Transon C and Dayer P (1993) Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4 -hydroxylation in human liver. Life Sci 52: Lowry OH, Rosebrough NJ, Farr AL and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: Masubuchi Y, Takahashii C, Fujio N, Horie T, Suzuki T, Imaoka S, Funae Y and Narimatsu S (1995) Inhibition and induction of cytochrome P450 isozymes after repetitive administration of imipramine in rats. Drug Metab Dispos 23: Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME and Birkett DJ (1988) Tolbutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 37: Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: Pumford NR, Myers TG, Davila JC, Highet RJ and Pohl LR (1993) Immunochemical detection of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac. Chem Res Toxicol 6: Seitz S, Kretz-Rommel A, Oude Elferink RP and Boelsterli UA (1998) Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2). Chem Res Toxicol 11: Shen S, Hargus SJ, Martin BM and Pohl LR (1997) Cytochrome P4502C11 is a target of diclofenac covalent binding in rats. Chem Res Toxicol 10: Shen S, Marchick MR, Davis MR, Doss GA and Pohl LR (1999) Metabolic activation of diclofenac by human cytochrome P450 3A4: role of 5-hydroxydiclofenac. Chem Res Toxicol 12: Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5 47. Stierlin H, Faigle JW, Sallmann A, Kung W, Richter WJ, Kriemler HP, Alt KO and Winkler T (1979) Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites. Xenobiotica 9: Tang W, Stearns RA, Bandiera SM, Zhang Y, Raab C, Braun MP, Dean DC, Pang J, Leung KH, Doss GA, et al. (1999a) Studies on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes: identification of glutathione conjugated metabolites. Drug Metab Dispos 27: Tang W, Stearns RA, Wang RW, Chiu SH and Baillie TA (1999b) Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac. Chem Res Toxicol 12: Wade LT, Kenna JG and Caldwell J (1997) Immunochemical identification of mouse hepatic protein adducts derived from the nonsteroidal anti-inflammatory drugs diclofenac, sulindac, and ibuprofen. Chem Res Toxicol 10: Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4: